2522
Yavuz Anacak(Ege University), Nuran Beşe(Turkcell (Turkey)), Ron Epelbaum(University of Bern), A.M. Mamusa, Yan-Xue Li(Shandong University), Mahmut Özşahin(University of Lausanne), Robert F. Miller(University College Hospital), Andrea N. Lucas(Institut Català d'Oncologia), N. Constantinou(Theageneio General Hospital), Anna Kowalczyk(University Clinical Centre)
International Journal of Radiation Oncology*Biology*Physics
October 15, 2006
Cited by 2
Related Papers
Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
|Current Medicinal Chemistry|2009|480
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
|British Journal of Cancer|2014|444
<sup>18</sup>F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients
|Journal of Nuclear Medicine|2009|381
Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy
|AIDS|2002|359
Curcumin and Gemcitabine in Patients With Advanced Pancreatic Cancer
|Nutrition and Cancer|2010|279